Literature DB >> 8615020

Use of lysolecithin-permeabilized infected-cell extracts to investigate the in vitro biochemical phenotypes of poxvirus ts mutations altered in viral transcription activity.

R C Condit1, J I Lewis, M Quinn, L M Christen, E G Niles.   

Abstract

Lysolecithin permeabilization of vaccinia virus-infected cells was employed to prepare extracts that support faithful transcription initiation in vitro on plasmids possessing early, intermediate, and late viral gene promoters. Conditions which optimize transcription from each promoter were defined. The in vitro system was used to investigate the multifunctional viral mRNA capping enzyme, which also functions as the viral early gene transcription termination factor (VTF) and a viral intermediate gene transcription initiation factor. A low level of signal-dependent termination of early gene transcription was observed in vitro which could be elevated by the addition of pure mRNA capping enzyme. VTF-dependent transcription termination was found to be restricted to templates that possessed an early promoter. This restriction mimics that observed in vivo and demonstrates that transcription termination is limited to RNA polymerase molecules that recognize early rather than intermediate or late gene promoters. Extracts prepared from cells infected at the nonpermissive temperature with a virus containing a ts mutation in gene D12L, which encodes the small subunit of VTF, are incapable of supporting both early gene transcription termination and intermediate gene transcription initiation. Both activities are restored upon addition of the purified wild-type mRNA capping enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615020     DOI: 10.1006/viro.1996.0177

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Phenotypic analysis of a temperature sensitive mutant in the large subunit of the vaccinia virus mRNA capping enzyme.

Authors:  Amber N Shatzer; Sayuri E M Kato; Richard C Condit
Journal:  Virology       Date:  2008-03-04       Impact factor: 3.616

2.  The vaccinia virus A18R DNA helicase is a postreplicative negative transcription elongation factor.

Authors:  Y Xiang; D A Simpson; J Spiegel; A Zhou; R H Silverman; R C Condit
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

3.  Vaccinia H5 is a multifunctional protein involved in viral DNA replication, postreplicative gene transcription, and virion morphogenesis.

Authors:  Susan M D'Costa; Travis W Bainbridge; Sayuri E Kato; Cindy Prins; Karen Kelley; Richard C Condit
Journal:  Virology       Date:  2010-03-05       Impact factor: 3.616

4.  Mapping and phenotypic analysis of spontaneous isatin-beta-thiosemicarbazone resistant mutants of vaccinia virus.

Authors:  Steven G Cresawn; Cindy Prins; Donald R Latner; Richard C Condit
Journal:  Virology       Date:  2007-03-01       Impact factor: 3.616

5.  Vaccinia virus early gene transcription termination factors VTF and Rap94 interact with the U9 termination motif in the nascent RNA in a transcription ternary complex.

Authors:  Linda A Christen; Sarah Piacente; Mohamed R Mohamed; Edward G Niles
Journal:  Virology       Date:  2008-05-01       Impact factor: 3.616

6.  Biochemical and biophysical properties of a putative hub protein expressed by vaccinia virus.

Authors:  Nicole E Kay; Travis W Bainbridge; Richard C Condit; Michael R Bubb; Reuben E Judd; Balasubramanian Venkatakrishnan; Robert McKenna; Susan M D'Costa
Journal:  J Biol Chem       Date:  2013-03-08       Impact factor: 5.157

7.  Determinants of vaccinia virus early gene transcription termination.

Authors:  Sarah Piacente; Linda Christen; Benjamin Dickerman; Mohamed R Mohamed; Edward G Niles
Journal:  Virology       Date:  2008-04-22       Impact factor: 3.616

8.  Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutant.

Authors:  Jessica Tate; Rachel L Boldt; Baron D McFadden; Susan M D'Costa; Nicholas M Lewandowski; Amber N Shatzer; Paul Gollnick; Richard C Condit
Journal:  Virology       Date:  2015-10-20       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.